Accout Center s.r.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
At Accout Center s.r.o. in Sahy, Slovakia, clinical research in gastroenterology focuses on common and chronic conditions affecting the intestines and colon. The main diseases studied include ulcerative colitis, Crohn's disease, and coeliac disease, with trials aimed at finding better ways to relieve symptoms, improve remission rates, and support long-term disease control.
- Research on ulcerative colitis and Crohn's disease to test new treatments for active inflammatory bowel disease
- Studies in coeliac disease focused on reducing gluten-related intestinal damage and improving gut health
- Trials designed to evaluate treatment effectiveness, safety, and sustained symptom control in digestive disorders
This site’s work reflects a strong interest in therapies for inflammatory bowel disease, especially approaches intended to help patients achieve and maintain clinical remission.
Immune System Phenomena
Clinical trials at this hospital/clinic also explore immune-related processes that drive intestinal inflammation. The research is centered on how the immune system contributes to diseases such as ulcerative colitis and Crohn's disease, with additional attention to immune responses linked to non-responsive coeliac disease.
- Immune-focused studies in ulcerative colitis and Crohn's disease to better control inflammation
- Research in coeliac disease examining immune reactions to gluten exposure and intestinal injury
- Trials assessing whether new therapies can improve remission, reduce mucosal inflammation, and support safer long-term care
These studies highlight a broader effort to understand and modulate immune-mediated digestive diseases through more effective treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Accout Center s.r.o.
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 3 | Unknown | 2024-09-04 | 2025-08-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.